{"id":"single-agent-iv-antibiotic-therapy-mssa","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Hypersensitivity/allergic reaction"},{"rate":"5-10%","effect":"Phlebitis at infusion site"},{"rate":"1-5%","effect":"Nausea/vomiting"},{"rate":"2-5%","effect":"Diarrhea"},{"rate":"1-3%","effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This represents a clinical protocol or treatment approach rather than a single novel drug entity. It typically involves beta-lactam antibiotics (such as nafcillin, oxacillin, or cefazolin) administered intravenously as monotherapy against MSSA infections. These agents work by binding to penicillin-binding proteins and disrupting peptidoglycan cross-linking in the bacterial cell wall, leading to cell lysis and death.","oneSentence":"Single-agent intravenous antibiotic therapy targets and kills methicillin-susceptible Staphylococcus aureus (MSSA) by inhibiting bacterial cell wall synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:11.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Methicillin-susceptible Staphylococcus aureus (MSSA) infections (bacteremia, endocarditis, osteomyelitis, pneumonia, skin/soft tissue infections)"}]},"trialDetails":[{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cefazolin","oxacillin","nafcillin","rifampin"],"phase":"marketed","status":"active","brandName":"Single Agent IV Antibiotic Therapy - MSSA","genericName":"Single Agent IV Antibiotic Therapy - MSSA","companyName":"West Virginia University","companyId":"west-virginia-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Single-agent intravenous antibiotic therapy targets and kills methicillin-susceptible Staphylococcus aureus (MSSA) by inhibiting bacterial cell wall synthesis. Used for Methicillin-susceptible Staphylococcus aureus (MSSA) infections (bacteremia, endocarditis, osteomyelitis, pneumonia, skin/soft tissue infections).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}